Today’s most significant insider transaction report is a Form 4 filing by Ares Management.
Ares revealed an additional purchase of roughly $2.9 million in Frontier Communications Parent $FYBR.
Expert technical analysis of financial markets by JC Parets
by David
Today’s most significant insider transaction report is a Form 4 filing by Ares Management.
Ares revealed an additional purchase of roughly $2.9 million in Frontier Communications Parent $FYBR.
by David
The most significant insider transaction on today’s list comes in a Form 4 filed by RA Capital Management.
The hedge fund revealed a purchase of roughly $14.7 million of Dice Therapeutics $DICE, increasing its ownership stake to 16%.
by David
Today’s most significant insider transaction report is a Form 4 filing by Ares Management, which revealed a purchase of roughly $26.4 million in Frontier Communications Parent $FYBR.
The hedge fund now owns 36 million shares, which represents an ownership stake of 14.3%.
by David
Today’s most significant insider transaction report is another Form 4 filing by Warren Buffett’s Berkshire Hathaway $BRK.A for Occidental Petroleum $OXY.
On Monday, Buffett disclosed an additional purchase of OXY shares worth roughly $216 million.
by David
The most significant insider transaction on today’s list comes in a Form 4 filed by RA Capital Management.
The hedge fund revealed a purchase of roughly $13.4 million of Dice Therapeutics $DICE, increasing its ownership stake to 14.3%.
by David
Mario Gabelli’s GAMCO Investors is back on our list.
GAMCO filed a 13D revealing an increase in ownership in Sinclair Broadcast Group $SBGI from 8.32% to 9.34%.
by David
The most significant insider transaction on today’s list comes in a Form 4 from Carl Icahn.
Icahn bought $30 million worth of Southwest Gas Holdings $SWX, increasing his ownership stake from 12.64% to 14.44%.
by David
The largest insider buy on today’s list comes in a Form 4 filing by Bihua Chen, the CEO of Cormorant Asset Management.
Chen revealed a purchase of $16.7 million in MoonLake Immunotherapeutics $MLTX.